Table 2.
Time course of eGFR, plasma oxalate, blood chemistry and SDS height of patients with PH1.
| Prior to CLKT/KALT (n = 10) | 6 months (n = 10) | 12 months (n = 10) | 18 months (n = 10) | 24 months (n = 10) | 30 months (n = 10) | |
|---|---|---|---|---|---|---|
| eGFR (ml/min/1.73 m2) | Treated with dialysis | 81 ± 12 | 75 ± 12 | 83 ± 9 | 80 ± 6 | 80 ± 6 |
| Bone pain (n) | 7 | 5 | 3 | 2 | – | – |
| Height (SDS) | −1.1 ± 0.4 | −1.1 ± 0.5 | −1.1 ± 0.3 | −0.9 ± 0.4 | −0.8 ± 0.3 | −0.8 ± 0.2 |
| Plasma oxalate (µmol/L) | 115 ± 40 | 12 ± 10 | 11 ± 8 | nm | nm | nm |
| PTH (pg/ml) | 258 ± 12 | 160 ± 110 | 55 ± 15 | 65 ± 15 | 60 ± 14 | 82 ± 1 |
| 25-hydroxy-vitamine D (ng/ml) | 28 ± 10 | 30 ± 8 | 22 ± 4 | 25 ± 12 | 24 ± 7 | 29 ± 6 |
| Calcium (mmol/L) | 2.3 ± 0.2 | 2.0 ± 0.4 | 2.0 ± 0.2 | 2.1 ± 0.2 | 2.1 ± 0.2 | 2.1 ± 0.4 |
| Phosphorus (mmol/L) | 3.4 ± 2.2 | 2.1 ± 0.9 | 1.8 ± 0.2 | 1.8 ± 0.8 | 1.9 ± 1.1 | 1.5 ± 0.3 |
| AP (U/L) | 538 ± 210 | 236 ± 73 | 229 ± 58 | 199 ± 48 | 210 ± 30 | 214 ± 15 |
Nm, not measured; eGFR, estimated glomerular filtration rate; AP, alkaline phosphatase; PTH, Parathyroid hormone; SDS, Standard deviation score.